異常ヘモグロビン症の市場動向・市場シェア・市場規模の予測 (2021-2028年)：タイプ (サラセミア・鎌状赤血球症・その他)・診断法・治療法・地域別

世界の異常ヘモグロビン症の市場規模は予測期間中10.8％のCAGRで推移し、2028年には157億米ドルの規模に成長すると予測されています。異常ヘモグロビン症に対する認知度の拡大、早期診断のための政府による取り組み、R&D投資の増加、有望な医薬品パイプラインの存在、高度な技術による診断プラットフォームなどの要因が同市場の成長を推進する見通しです。

当レポートでは、世界の異常ヘモグロビン症の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、タイプ・診断法・治療法・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

• 普及・成長の見通しマッピング
• ヘモグロビン症の疫学評価
• 市場可変因子の分析
• 市場における制約
• SWOT分析
• ポーターのファイブフォース分析

第4章 市場予測・動向分析：タイプ別

• サラセミア
  • アルファサラセミア
  • ベータサラセミア
• 鎌状赤血球症
• その他

第5章 市場予測・動向分析：診断別

• サラセミアの診断
  • 血液検査
  • 遺伝子検査
  • 出生前遺伝子検査
  • 着床前遺伝子診断
  • 電気泳動
  • その他
• 鎌状赤血球症の診断
  • 血液検査
  • 遺伝子検査
  • 出生前遺伝子検査
  • 電気泳動
  • その他
• その他の疾患の診断
  • 血液検査
  • 遺伝子検査
  • 出生前遺伝子検査
  • 電気泳動
  • その他

第6章 市場予測・動向分析：治療別

• サラセミア
  • 輸血
  • 鉄キレート療法
  • 骨髄移植
  • その他
• 鎌状赤血球症
  • 輸血
  • ヒドロキシ尿素
  • 骨髄移植
  • その他
• その他
  • 輸血
  • ヒドロキシ尿素
  • 鉄キレート療法
  • 骨髄移植
  • その他

第7章 市場予測・動向分析：地域・主要国別

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ロシア
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • シンガポール
  • オーストラリア
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • アラブ首長国連邦
  • サウジアラビア

第8章 競合分析

• 主要企業・近年の展開・影響分析
• ベンダー情勢
• 主な取引・戦略的提携
• 企業プロファイル
  • Sangamo Therapeutics
  • bluebird bio, Inc.
  • Global Blood Therapeutics, Inc.
  • Pfizer, Inc.
  • Emmaus Life Sciences, Inc.
  • Prolong Pharmaceuticals, LLC
  • Celgene Corporation (BMS)
  • Bioverativ Inc. (Sanofi)
  • Gamida Cell
  • Novartis AG

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Descriptive Analysis of the Age at Diagnosis Laboratory Evaluation of Hbs, Hbf, and Hemolytic State and Complications Recorded
• Table 4 List Of Normal Human Hemoglobin
• Table 5 Hemoglobinopathies Market: Product Pipeline
• Table 6 Leading Market Players Anticipated to Witness Highest Growth
• Table 7 North America Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
• Table 8 North America Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 9 North America Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 10 North America Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 11 U.S. Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 12 U.S. Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 13 U.S. Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 14 Canada Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 15 Canada Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 16 Canada Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 17 Europe Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
• Table 18 Europe Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 19 Europe Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 20 Europe Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 21 U.K. Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 22 U.K. Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 23 U.K. Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 24 Germany Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 25 Germany Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 26 Germany Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 27 France Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 28 France Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 29 France Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 30 Spain Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 31 Spain Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 32 Spain Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 33 Italy Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 34 Italy Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 35 Italy Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 36 Russia Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 37 Russia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 38 Russia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 39 Asia Pacific Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
• Table 40 Asia Pacific Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 41 Asia Pacific Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 42 Asia Pacific Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 43 Japan Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 44 Japan Hemoglobinopathies Market, By Diagnosis 2017 - 2028 (USD Million)
• Table 45 Japan Hemoglobinopathies Market, By Therapy 2017 - 2028 (USD Million)
• Table 46 China Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 47 China Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 48 China Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 49 India Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 50 India Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 51 India Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 52 South Korea Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
• Table 53 South Korea Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 54 South Korea Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 55 Singapore Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
• Table 56 Singapore Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 57 Singapore Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 58 Australia Hemoglobinopathies Market, By Type 2017 - 2028 (USD Million)
• Table 59 Australia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 60 Australia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 61 Latin America Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
• Table 62 Latin America Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 63 Latin America Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 64 Latin America Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 65 Brazil Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 66 Brazil Hemoglobinopathies Market, By Diagnosis 2017 - 2028 (USD Million)
• Table 67 Brazil Hemoglobinopathies Market, By Therapy 2017 - 2028 (USD Million)
• Table 68 Mexico Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 69 Mexico Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 70 Mexico Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 71 Argentina Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 72 Argentina Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 73 Argentina Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 74 Middle East & Africa Hemoglobinopathies Market, By Country, 2017 - 2028 (USD Million)
• Table 75 Middle East & Africa Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 76 Middle East & Africa Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 77 Middle East & Africa Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 78 South Africa Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 79 South Africa Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 80 South Africa Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 81 Saudi Arabia Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 82 Saudi Arabia Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 83 Saudi Arabia Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)
• Table 84 United Arab Emirates Hemoglobinopathies Market, By Type, 2017 - 2028 (USD Million)
• Table 85 United Arab Emirates Hemoglobinopathies Market, By Diagnosis, 2017 - 2028 (USD Million)
• Table 86 United Arab Emirates Hemoglobinopathies Market, By Therapy, 2017 - 2028 (USD Million)

List of Figures

• Fig. 1 Hemoglobinopathies market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Hemoglobinopathies market snapshot
• Fig. 10 Penetration and growth prospect mapping
• Fig. 11 Hemoglobinopathies market driver impact
• Fig. 12 Prevalence of hemoglobinopathies gene carriers
• Fig. 13 Hemoglobinopathies market restraint impact
• Fig. 14 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 15 Porter's five forces analysis
• Fig. 16 Hemoglobinopathies market: Type outlook and key takeaways
• Fig. 17 Hemoglobinopathies market: Type movement analysis
• Fig. 18 Thalassemia market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 19 Sickle cell disease market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 20 Other hemoglobin (Hb) variants market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 21 Hemoglobinopathies market: Diagnosis outlook and key takeaways
• Fig. 22 Hemoglobinopathies market: Diagnosis movement analysis
• Fig. 23 Thalassemia diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 24 Sickle cell disease diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 25 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 26 Hemoglobinopathies market: Therapy outlook and key takeaways
• Fig. 27 Hemoglobinopathies market: Therapy movement analysis
• Fig. 28 Thalassemia therapy market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 29 Sickle cell disease therapy market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 30 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 31 Hemoglobinopathies market: Regional outlook and key takeaways
• Fig. 32 Hemoglobinopathies market: Regional movement analysis
• Fig. 33 North America
• Fig. 34 North America market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 35 U.S.
• Fig. 36 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 37 Canada
• Fig. 38 Canada market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 39 Europe
• Fig. 40 Europe market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 41 U.K.
• Fig. 42 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 43 Germany
• Fig. 44 Germany market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 45 France
• Fig. 46 France market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 47 Italy
• Fig. 48 Italy market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 49 Spain
• Fig. 50 Spain market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 51 Russia
• Fig. 52 Russia market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 53 Asia Pacific
• Fig. 54 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 55 Japan
• Fig. 56 Japan market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 57 China
• Fig. 58 China market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 59 India
• Fig. 60 India market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 61 South Korea
• Fig. 62 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 63 Singapore
• Fig. 64 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 65 Australia
• Fig. 66 Australia market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 67 Latin America
• Fig. 68 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 69 Brazil
• Fig. 70 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 71 Mexico
• Fig. 72 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 73 Argentina
• Fig. 74 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 75 Middle East & Africa
• Fig. 76 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 77 South Africa
• Fig. 78 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 79 United Arab Emirates
• Fig. 80 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 81 Saudi Arabia
• Fig. 82 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
• Fig. 83 Ansoff Matrix
• Fig. 84 Competition categorization
• Fig. 85 Strategic framework
• Fig. 86 Strategy mapping

Hemoglobinopathies Market Growth & Trends

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic stem cell transplantation, coupled with a promising pipeline, is expected to propel market growth. Moreover, the presence of regulatory agencies, such as the FDA, which are working toward improving drug approval rate by granting accelerated approval for hemoglobinopathies drugs, is expected to drive the market. For instance, in 2019, the FDA has approved four novel drugs: Reblozyl by Bristol-Myers Squibb Company, Adakveo by Novartis AG, Zynteglo by bluebird bio, Inc., and Oxbryta by Global Blood Therapeutics, Inc. for the treatment of hemoglobinopathies.

Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate. SCAI also raises funds for individuals affected with sickle cell diseases (SCDs) and provides research funding. Moreover, governments of Middle Eastern and Asian countries provide funds for R&D of hemoglobinopathies treatment. For instance, various programs undertaken by governments, such as thalassemia screening in neonates and providing medicines, are impacting the market growth positively.

The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy. For instance, in February 2019, the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) was launched by Global Blood Therapeutics, Inc. in order to provide research funding for novel SCD projects, with an aim to expand the access to optimal healthcare for sickle cell disease.

Biopharmaceutical companies are collaborating with nonprofit organizations to promote public awareness about hemoglobinopathies. For instance, in June 2018, the Sickle Cell Disease Association of America partnered with Emmaus Life Sciences, Inc. to provide online educational tools to sickle cell patients, friends, clinicians, caregivers, and researchers for spreading awareness about complications associated with SCD.

An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. The National Heart, Lung, and Blood Institute (NHLBI) has significantly invested in research & development in sickle cell disease. The NHLBI supports research work through various initiatives. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.

Gene therapy has emerged as a promising treatment option for managing hemoglobin disorder as it targets the underlying genetic cause of the condition through the administration of one-time gene therapy and significantly reduces the need for blood transfusions. The current pipeline of gene therapy products includes CTX001 (CRISPR Therapeutics), BIVV003 (Sangamo Therapeutics, Inc. & Bioverativ Inc), and HGB-206 (bluebird bio, Inc).

Hemoglobinopathies Market Report Highlights

• Based on type, sickle cell disease accounted for the largest share of 56.6% in 2020 and is anticipated to maintain its lead over the forecast period

• The newborn patient population with sickle cell anemia is anticipated to reach 400,000 by 2050. Half of the global sickle cell anemia burden is present in India, Nigeria, and the Democratic Republic of the Congo

• By therapy, in the thalassemia segment, the blood transfusion segment held the largest market share in 2020 and is estimated to dominate the market throughout the forecast period

• Asia Pacific is expected to witness the fastest growth over the forecast period owing to a large potential patient base and high unmet medical needs in the region

• North America held the largest market share in 2020 due to government initiatives focusing on the development of new therapies and better reimbursement scenario

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Estimates and Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country-wise Market Estimation Using Bottom-Up Approach
• 1.7 Global Market: CAGR Calculation
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 Objectives
  • 1.10.1 Objective 1:
  • 1.10.2 Objective 2:
• 1.11 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Summary

Chapter 3 Global Hemoglobinopathies Market Variables, Trends & Scope

• 3.1 Penetration and Growth Prospect Mapping
• 3.2 Epidemiology Assessment of Hemoglobinopathies
  • 3.2.1 Sickle cell disease
  • 3.2.2 Thalassemia
• 3.3 Market Variable Analysis
  • 3.3.1 Increasing prevalence of hemoglobinopathies in under-developed countries
  • 3.3.2 High unmet needs
  • 3.3.3 Increasing R&D investment
  • 3.3.4 Initiatives to improve disease awareness levels
• 3.4 Market Restraint Analysis
  • 3.4.1 Lack of healthcare infrastructure
  • 3.4.2 High cost of treatment
• 3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• 3.6 Porter's Five Forces Analysis

Chapter 4 Hemoglobinopathies Market - Segment Analysis, by Type, 2017 - 2028 (USD Million)

• 4.1 Market: Type Movement Analysis
• 4.2 Thalassemia
  • 4.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)
  • 4.2.2 Alpha Thalassemia
  • 4.2.3 Beta thalassemia
• 4.3 Sickle Cell Disease
  • 4.3.1 Market estimates and forecast, 2017 - 2028 (USD Million)
• 4.4 Other Hemoglobin (Hb) Variants
  • 4.4.1 Market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 5 Hemoglobinopathies Market - Segment Analysis, by Diagnosis, 2017 - 2028 (USD Million)

• 5.1 Hemoglobinopathies Market: Diagnosis Movement Analysis
• 5.2 Thalassemia Diagnosis
  • 5.2.1 Thalassemia diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
  • 5.2.2 Blood Test
  • 5.2.3 Genetic Test
  • 5.2.4 Prenatal Genetic Test
  • 5.2.5 Pre-implantation Genetic Diagnosis
  • 5.2.6 Electrophoresis
  • 5.2.7 Others
• 5.3 Sickle Cell Disease Diagnosis
  • 5.3.1 Sickle cell disease diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
  • 5.3.2 Blood Test
  • 5.3.3 Genetic Test
  • 5.3.4 Prenatal Genetic Test
  • 5.3.5 Electrophoresis
  • 5.3.6 Others
• 5.4 Other Hemoglobin (Hb) Variants Diagnosis
  • 5.4.1 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
  • 5.4.2 Blood Test
  • 5.4.3 Genetic Test
  • 5.4.4 Prenatal Genetic Test
  • 5.4.5 Electrophoresis
  • 5.4.6 Others

Chapter 6 Hemoglobinopathies Market - Segment Analysis, by Therapy, 2017 - 2028 (USD Million)

• 6.1 Hemoglobinopathies Market: Therapy Movement Analysis
• 6.2 Thalassemia Therapy
  • 6.2.1 Thalassemia therapy market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.2.2 Blood Transfusion
  • 6.2.3 Iron Chelation Therapy
  • 6.2.4 Bone Marrow Transplant
  • 6.2.5 Others
• 6.3 Sickle Cell Disease Therapy
  • 6.3.1 Sickle cell disease therapy market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.3.2 Blood Transfusion
  • 6.3.3 Hydroxyurea
  • 6.3.4 Bone Marrow Transplant
  • 6.3.5 Others
• 6.4 Other Hemoglobin (Hb) Variants Therapy
  • 6.4.1 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.4.2 Blood Transfusion
  • 6.4.3 Hydroxyurea
  • 6.4.4 Iron Chelation Therapy
  • 6.4.5 Bone Marrow Transplant
  • 6.4.6 Others

Chapter 7 Hemoglobinopathies Market - Segment Analysis, by Region, 2017 - 2028 (USD Million)

• 7.1 Hemoglobinopathies Market: Regional Movement Analysis
• 7.2 North America
  • 7.2.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
• 7.3 Canada
  • 7.3.1.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
• 7.4 Europe
  • 7.4.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4.2 U.K.
    • 7.4.2.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4.3 Germany
    • 7.4.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4.4 France
    • 7.4.4.1 France market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4.5 Italy
    • 7.4.5.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4.6 Spain
    • 7.4.6.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4.7 Russia
    • 7.4.7.1 Russia market estimates and forecast, 2017 - 2028 (USD Million)
• 7.5 Asia Pacific
  • 7.5.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5.2 Japan
    • 7.5.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5.3 China
    • 7.5.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5.4 India
    • 7.5.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5.5 South Korea
    • 7.5.5.1 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5.6 Singapore
    • 7.5.6.1 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5.7 Australia
    • 7.5.7.1 Australia market estimates and forecast, 2017 - 2028 (USD Million)
• 7.6 Latin America
  • 7.6.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.6.2 Brazil
    • 7.6.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.6.3 Mexico
    • 7.6.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.6.4 Argentina
    • 7.6.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
• 7.7 Middle East & Africa
  • 7.7.1 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.7.2 South Africa
    • 7.7.2.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.7.3 United Arab Emirates
    • 7.7.3.1 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.7.4 Saudi Arabia
    • 7.7.4.1 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 8 Competitive Analysis

• 8.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.1.1 Ansoff matrix
  • 8.1.2 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
  • 8.1.3 Innovators
  • 8.1.4 Market Leaders
• 8.2 Vendor Landscape
  • 8.2.1 List of key distributors and channel partners
  • 8.2.2 Key customers
  • 8.2.3 Strategic framework
• 8.3 Major Deals and Strategic Alliances Analysis
  • 8.3.1.1 New product launch
  • 8.3.1.2 Mergers and acquisitions
  • 8.3.1.3 Expansion
  • 8.3.1.4 Partnerships
  • 8.3.1.5 Marketing & promotions
• 8.4 Company Profiles
  • 8.4.1 Sangamo Therapeutics
    • 8.4.1.1 Company overview
    • 8.4.1.2 Financial performance
    • 8.4.1.3 Product benchmarking
    • 8.4.1.4 Strategic initiatives
  • 8.4.2 bluebird bio, Inc.
    • 8.4.2.1 Company overview
    • 8.4.2.2 Financial performance
    • 8.4.2.3 Product benchmarking
    • 8.4.2.4 Strategic initiatives
  • 8.4.3 Global Blood Therapeutics, Inc.
    • 8.4.3.1 Company overview
    • 8.4.3.2 Financial performance
    • 8.4.3.3 Product benchmarking
    • 8.4.3.4 Strategic initiatives
  • 8.4.4 Pfizer, Inc.
    • 8.4.4.1 Company overview
    • 8.4.4.2 Financial performance
    • 8.4.4.3 Product benchmarking
    • 8.4.4.4 Strategic initiatives
  • 8.4.5 Emmaus Life Sciences, Inc.
    • 8.4.5.1 Company overview
    • 8.4.5.2 Financial performance
    • 8.4.5.3 Product benchmarking
    • 8.4.5.4 Strategic initiatives
  • 8.4.6 Prolong Pharmaceuticals, LLC
    • 8.4.6.1 Company overview
    • 8.4.6.2 Product benchmarking
    • 8.4.6.3 Strategic initiatives
  • 8.4.7 Celgene Corporation (BMS)
    • 8.4.7.1 Company overview
    • 8.4.7.2 Financial performance
    • 8.4.7.3 Product benchmarking
    • 8.4.7.4 Strategic initiatives
  • 8.4.8 Bioverativ Inc. (Sanofi)
    • 8.4.8.1 Company overview
    • 8.4.8.3 Product benchmarking
    • 8.4.8.4 Strategic initiatives
  • 8.4.9 Gamida Cell
    • 8.4.9.1 Company overview
    • 8.4.9.2 Financial performance
    • 8.4.9.3 Product benchmarking
    • 8.4.9.4 Strategic initiatives
  • 8.4.10 Novartis AG
    • 8.4.10.1 Company overview
    • 8.4.10.2 Financial Performance
    • 8.4.10.3 Product Benchmarking
    • 8.4.10.4 Strategic initiatives